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Introduction
Chronic idiopathic inflammatory bowel disease (IBD) cases
are on the rise, with approximately 6.8 million people diag-
nosed in 2017 [1]. Diagnosing the two main forms of IBD,
ulcerative colitis (UC) and Crohn’s disease (CD), involves a
combination of clinical history, laboratory findings, imaging,
endoscopy and histology [2].
The histopathological diagnosis of IBD is based on a com-
bination of microscopic findings, with consideration of clini-
cal data that include the patient’s age, symptoms, duration of
symptoms and endoscopic results [3–17].
CD is a chronic, progressively destructive disease with an
intermittent course in most cases. UC is most often described as
relapsing and remitting, with symptoms of active disease that
alternate with periods of clinical quiescence called remission
[18, 19]. Until recently, therapeutic strategies in both diseases
aimed to achieve adequate control of gastrointestinal inflamma-
tion. In recent years, however, mucosal healing has become the
key treatment goal in IBD. It is associated with improved clin-
ical outcomes, prolonged remission, fewer hospitalizations and
decreased probability for surgery [20–36]. Patients with
mucosal healing have lower rates of clinical relapse compared
to those with evidence of active or quiescent disease.
Endoscopic evaluation without histology, however, may be in-
sufficient to deem treated IBD mucosa as completely healed
[34, 36]. Furthermore, histologic identification of active disease
has also been shown to better predict the development of neo-
plasia in patients with UC compared to endoscopic assessment
of activity [30–32, 34, 37]. The fact that concordance between
endoscopic and histological remission is moderate only—with
histological remission being superior—underscores the neces-
sity of incorporating histologic methods of activity scoring into
clinical trials [34]. In fact, in 2016, the Food and Drug
Administration (FDA) of the United States Department of
Health and Human Services recommended that histologic as-
sessment be used in conjunction with endoscopy [38].
A number of histologic indices for assessing activity in UC
and CD exist. Nevertheless, they all have limitations, includ-
ing lack of full validation, difficulty of usage and heterogene-
ity in their standards for distinguishing between quiescent dis-
ease and histologic normalization [39, 40]. Moreover, there is
also a need for standardization of biopsy procedures in UC
and CD on the endoscopic end.
Recommendations for biopsy procedures and IBD scoring
exist from many internationally recognized organizations,
such as the European Crohn’s and Colitis Organisation
(ECCO), the World Gastroenterology Organisation (WGO),
the British Society of Gastroenterology (BSG), the
International Organization for the Study of Inflammatory
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Bowel Diseases (IOIBD), the American College of
Gastroenterology (ACG) and the American Society for
Gastrointestinal Endoscopy (ASGE). Some of them have re-
cently been updated [17, 19, 28, 41–51].
However, in practice, these existing recommendations are
not widely adhered to and there is still a need for standardizing
the number of IBD biopsies, the locations they are taken from
and an accepted validated IBD histologic assessment tool for
daily practice.
For these reasons, the objectives of the 2020 International
Consensus Conference on IBD Activity Scoring were (i) to
review existing recommendations and to agree upon ten rec-
ommendations with the highest impact to maximize diagnos-
tic information from biopsies for UC and CD and (ii) to agree
on a simple, histologic scoring system for both types of IBD
that is able to distinguish between quiescent disease and mu-
cosal healing and has potential for use in daily routine practice
as well as for clinical trials.
Material and methods
Consensus process
The meeting took place from the 8th to the 10th of January
2020 at the Institute of Pathology of the Friedrich-Alexander
University in Erlangen, Germany, with participants from 12
countries. Six sessions comprising presentations, discussions
and group microscopy sessions took place. The conference
was followed by a validation process of the consensus-ap-
proved scoring index. This involved individual member eval-
uations of digitally scanned IBD biopsy slides.
Steering committee and participants
The steering committee (MN, AH and the chairman MV)
organized the meeting in Erlangen. Twenty-seven participants
with expertise in IBD from the USA, Canada and Europe were
invited to attend the face-to-face meeting, and 25 agreed to
participate (17 gastrointestinal pathologists, 6 gastroenterolo-
gists and two translational researchers). Five were unable to
attend but participated in the post-meeting validation of the
agreed-upon scoring system aswell as the voting at final ballot
according to a modified Delphi panel. All participants were
voting members.
Methodological exactness
Search strategy and sources of evidence
The recommendations that reached consensus were based on
peer-reviewed publications in addition to expert opinions, ac-
cepted practice standards and consensus. To obtain consensus,
a two-round modified Delphi process was used. For this pur-
pose, two rounds of systematic literature searches regarding
IBD and activity scoring on PubMed, the Cochrane Library
and EMBASE were performed. The first took place prior to
the meeting and was circulated for review to all of the partic-
ipants. At the end of the face-to-face meeting, a first voting
round on the developed statements took place. Additional lit-
erature from a second literature search was added post-meet-
ing using combinations of key words such as “IBD”, “UC”,
“CD”, “histopathology” and “activity”. Six months post-
meeting, a final anonymous Delphi questionnaire round took
place. Participants were asked to review and reconsider their
initial ratings for the developed statements on a circulated
questionnaire using a 5-point Likert scale (5 = agree (100%),
4 = partly agree (75%), 3 = neutral (50%), 2 = partly disagree
(25%), 1 = disagree (0%)) [41, 42]. Strength of consensus was
graded as follows: < 75%, no consensus; 75–95%, consensus;
and > 95%, strong consensus.
Evidence levels and recommendation grades
The literature was rated according to the evidence classifica-
tion of the Oxford Centre for Evidence-based Medicine
(OCEBM), using the 2011 version (supplemental Table 1)
[52].
Evidence and recommendations from established clinical
and pathological guidelines were also taken into account, in-
cluding documents from the ECCO, the ASGE, the WGO, the
ACG, the IOIBD, the Updated S3-Guideline of the German
Society for Digestive and Metabolic Diseases (DGVS), the
updated BSG guidelines and a practical guide on tissue path-
ways for gastrointestinal and hepatopancreatobiliary patholo-
gy [2, 41, 43–51, 53–55].
Evidence levels (ELs) and grades of the recommendations
are given below where possible. In accordance with the
OCEBM, recommendation grades are defined as the follow-
ing: A, consistent level 1 studies; B, consistent level 2 or 3
studies or extrapolations from level 1 studies; C, level 4 stud-
ies of extrapolations from level 2 or 3 studies; and D, level 5
evidence or troublingly consistent or inclusive studies of any
level.
The recommendations, rather than being rules, are intended
to help endoscopists maximize the potential diagnostic infor-
mation they can render from biopsies to optimize their pa-
tients’ care. An overview of the consensus process is available
as supplemental Fig. 1.
Microscopy sessions
Prior to the meeting, haematoxylin and eosin (H&E)-stained
slides of 59 UC large bowel biopsy cases and 25 CD biopsy
sets from large bowel, terminal ileum and stomach were dig-
italized at the Institute of Pathology, Bayreuth, using the slide
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scanner NanoZoomer S360 (Hamamatsu, Herrsching am
Ammersee, Germany). All participants had access to the slides
prior to the meeting on a virtual, password-secured platform
(software: NDP.view 2; Hamamatsu, Herrsching am
Ammersee, Germany). Microscopy sessions during the face-
to-face meeting allowed for group discussions of selected
cases around a multi-headed microscope (Olympus BX53;
Olympus, Hamburg, Germany).
Presentations
The conference presentations comprised the scientist’s (CB),
the clinician’s (MN) and the pathologist’s (MV) views
concerning IBD activity scoring, along with their field-specif-
ic needs for an approved scoring system.
Results and discussion
Recommendations
An overview of the 10 recommendations that achieved con-
sensus is shown in Table 1.
Recommendation 1 If colonoscopic biopsies are being taken
for the diagnosis of chronic idiopathic IBD, the samples
should be sent in separate, designated containers, particular-
ly biopsies of the rectum (vote: strong consensus (95%), level
of evidence: 1a–2b, recommendation grade: B).
Evidence and decision When the initial diagnosis of IBD is
suspected, current guidelines and consensus papers recommend
an ileocolonoscopy with biopsies from the terminal ileum as
well as from each colonic segment: caecum, ascending colon,
transverse colon, descending colon, sigmoid and rectum [2, 19,
43, 45, 46, 56, 57]. Rather than pooling biopsies from multiple
sites into the same container, the biopsies should be delivered to
the pathologist in separate, designated containers. This assists in
distinguishing between UC and CD and for properly evaluating
the distribution of the disease [2, 4, 43, 53, 56, 58, 59] (EL 2a–
2b). The importance of proper sampling and designating biopsy
sites is exemplified in patients who exhibit unusual distribution
of inflammation. Without clear designation of separate sites, it
is challenging to diagnose CD in patients who lack terminal
ileum involvement, or UC in patients who have proctitis, caecal
patch and backwash ileitis. Other reasons to separately desig-
nate bowel sites are important to note. For one, some cases can
be classified as UC or CD only from the course of the disease.
Tracking the patients’ site-specific histology over time can help
establish the diagnosis [60–65] (EL 1a–2b). Moreover, treat-
ment may alter the distribution of inflammation and it may be
useful to follow the effects of therapy for each bowel site. This
can also lead to accurately establishing if histologic normaliza-
tion has occurred as a result of therapy [66–73] (EL 1a–2a).
Finally, designating different bowel sites can have treatment
implications. Local treatment with 5-aminosalicylic acid or ste-
roids is sufficient in most cases of UC that are restricted to the
rectum. However, solitary rectal involvement may not be con-
firmed histologically if the patients’ rectal and colonic biopsies
are pooled [71–73] (EL 1a).








1. If colonoscopic biopsies are being taken for the diagnosis of chronic idiopathic IBD, the samples
should be sent in separate, designated containers, particularly biopsies of the rectum
95 1a–2b B
2. 2 or more tissue samples from separate areas within the same bowel segment should be sent in each
designated container
98 1a–2b B
3. If Crohn’s disease is in question, additional biopsies from the upper gastrointestinal tract should also
be considered
92 1b–3a C
4. Assessing the degree of activity should be carried out on the worst affected biopsy 100 1a–2a B
5. The information between pathologist and clinician should include core features that are relevant for
the IBD diagnosis as well as for IBD activity scoring
98 1a–3b C
6. The histological assessment should evaluate the distribution of overall findings, the presence of
chronic injury and the activity of inflammation
100 1a–3b C
7. The scoring system (the IBD-DCA score) developed by the consensus group based on the factors of
distribution (D) of changes, chronic injury (C) and activity of inflammation (A) is a proposal for a
standardized and user-friendly tool for histologic activity assessment
98 2b B
8. The pathology report can include routine text as well as the IBD-DCA score as qualitative and
quantitative information for clinicians
93 5 D
9. Activity scoring is ideally performed for every container separately 83 1b–3b C
10. The IBD-DCA score is suggested for use in daily routine practice 95 5 D
583Virchows Arch (2021) 478:581–594
Recommendation 2 Two or more tissue samples from sepa-
rate areas within the same bowel segment should be sent in
each designated container (vote: strong consensus (98%),
level of evidence: 1a–2b, recommendation grade: B).
Evidence and decision Current scoring systems have been
applied to biopsy material collected under diverse protocols
that include different numbers of tissue samples from different
sections of the large bowel. In fact, there are protocols that
allow for the bare minimum of rectum-only samples. There is
clearly a need to standardize sampling protocols in clinical
trials in order to optimize comparisons between treatment out-
comes [20, 74] (EL 2a–2b). Our recommendation to sample a
minimum of 2 biopsies from separate areas within the same
bowel segment is therefore intended to standardize and opti-
mize biopsy evaluation. This is supported byMosli et al. [75].
They concluded that it is imperative to obtain at least 2 mu-
cosal biopsy samples for evaluation of UC as the disease
changes during the natural disease course and with local and
systemic treatment [60, 74–76] (EL 1b–2a). Collecting more
than one biopsy also decreases the problem of sample quality
and tissue orientation issues. Additionally, as suggested by the
ECCO recommendations, biopsies can be properly oriented
by use of acetate strips [49, 77]. Further support for the req-
uisite number of biopsy samples is seen in ECCO guidelines,
which recommend that a minimum of two biopsies per bowel
site be obtained to diagnose CD. For CD, samples should
preferably be obtained from both diseased and uninvolved
areas [43, 78–86] (EL 1a–2a). If samples are taken only from
macroscopically or endoscopically suspicious areas, a pathol-
ogist without endoscopic information may not be able to in-
corporate evidence of discontinuous disease distribution to
support an accurate diagnosis of CD. As such, our recommen-
dation advises sampling from separate areas within the same
bowel segment and also proper labelling of the containers to
ensure that the pathologist receives proper information about
the biopsies’ origin.
Recommendation 3 If Crohn’s disease is in question, addi-
tional biopsies from the upper gastrointestinal tract should
also be considered (vote: consensus (92%), level of evidence:
1b–3a, recommendation grade: C).
Evidence and decisionMicroscopic inflammation of the upper
gastrointestinal (GI) tract is quite common in CD and compar-
atively rare in UC [87] (EL 2b). The reported frequency of
upper GI tract involvement in CD varies widely, from 6.5% in
a recent analysis of the Swiss IBD Cohort Study Group to
40.7% in a study of paediatric CD cases, even in the absence
of specific upper gastrointestinal symptoms. As such,
Castellaneta et al. [88] concluded that upper GI tract endosco-
py should be part of the first-line investigation in all new cases
suspected of IBD, particularly as the absence of specific upper
GI symptoms does not exclude the presence of upper GI in-
flammation [87, 89] (EL 2b). Patches of acute inflammation of
the stomach and duodenum as well as deep acute inflamma-
tion of the duodenum raise strong suspicion for CD in
Helicobacter pylori (HP)-negative patients. In fact, the histo-
logical pattern of a “focally enhanced” gastritis in HP-negative
patients with CD was first described in 1997 by Oberhuber et
al. [90] (a participant of the current consensus conference).
Overall, they found granulomas and/or a focally enhanced
gastritis in 76% of HP-negative patients with CD and in
0.8% of controls. Moreover, there was no correlation between
the presence of focally enhanced gastritis and clinical findings
[90] (EL 1b). It should be noted, however, that the presence of
granulomas is helpful but occurs in only 9–14.6% of upper GI
biopsies [90–92] (EL 1b–3a). In summary, if CD is the diag-
nosis of clinical concern, the consensus group recommends
additional duodenogastroscopy to help consolidate a diagno-
sis of CD. A minimum of 2 biopsies each from duodenum,
antrum and corpus sites should be sent to the pathologist in
separate containers [43, 44].
Recommendation 4 Assessing the degree of activity should be
carried out on the worst affected biopsy (vote: strong consen-
sus (100%), level of evidence: 1a–2a, recommendation grade:
B).
Evidence and decisionAssessing the histologic activity of UC
is especially important in monitoring treatment follow-up. For
clinical trials, scoring is typically performed on the sample
exhibiting the highest activity as this may be the most impor-
tant factor in the further evolution of the disease [75] (EL 1a).
It is also important to grade activity based on the most dis-
eased biopsy fragment because it is paramount in establishing
whether histologic mucosal healing has truly been achieved.
The consensus participants agreed to define histologic muco-
sal healing as normal mucosa without any pathological chang-
es. This includes the absence of changes seen in quiescent
colitis, which encompasses architectural abnormalities as well
as increased chronic inflammatory infiltrates. Therefore, grad-
ing should be done on the most affected biopsy to indicate if
quiescent colitis is present, as quiescent disease is not consid-
ered equivalent to the histologic normalization required to
meet criteria for histologic mucosal healing. A detailed de-
scription of the normal histology of the colon has been pub-
lished by Levine and Haggitt [93] (EL 2a).
Recommendation 5 The information between pathologist and
clinician should include core features that are relevant for the
IBD diagnosis as well as for IBD activity scoring (vote: strong
consensus (98%), level of evidence: 1a–3b, recommendation
grade: C).
The following core features (or key elements) refer to de-
tails that are essential for the pathologist to be able to establish
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a diagnosis of IBD. They also, in turn, refer to information that
the pathologist should communicate to the clinician for the
patient’s management.
The core features to be communicated to the pathologist by
the clinician include:
& Patient’s age [92, 94–101] (EL 1a–2b)
In the vast majority, patients with UC and CD are usu-
ally diagnosed in their 20s and 30s, although IBD occurs
at any age.
& Type and duration of symptoms [8, 10, 12, 45] (EL 2a–2b)
This information is important given that infectious co-
litis is one of the main considerations in the differential
diagnosis of IBD. The symptoms of infectious colitis can
be similar to IBD; however, they usually last for less than
1 month. Therefore, a diagnosis of IBD is more likely with
longer duration of symptoms.
& Endoscopic findings: The distribution and type of abnor-
malities noted on endoscopy should be relayed to the pa-
thologist, along with the key clinical question the pathol-
ogist is being asked to address.
& Diagnosis of CD or UC if already known
& Status of current treatment in known IBD patients [22, 24,
25, 45] (EL 1a–2b)
Therapy status is an important piece of information to
provide as pathologists can then determine whether treat-
ment has achieved the desired endpoint of histologic mu-
cosal healing. For example, if a pathologist with access to
previous biopsy findings and therapy information encoun-
ters normal mucosa in areas of known, formerly active
IBD, they can establish in their report that histologic nor-
malization has occurred, to indicate that the mucosa has, in
fact, normalized due to treatment.
& Specific, designated sites from which biopsies have been
taken [45, 55].
Biopsies from different bowel segments should be sub-
mitted in such a way that their site of origin can be deter-
mined reliably. This issue is discussed further with state-
ment 2, mentioned previously.
Core histologic features to be communicated to the clini-
cians include:
& Diagnosis of IBD or others
& Distinction between UC and CD [16, 44–51, 102] (EL 1b–
2a)
& The term “indeterminate colitis” should be avoided as it
causes confusion and can be used incorrectly. Rather, it is
recommended that a pathologist state that IBD is present
and the features favour one disease type over the other, but
that definitive classification may depend on the clinical
course.
& Exclusion of dysplasia or malignancy [62, 64]
& Information regarding the adequacy and/or limitations of
the submitted material, i.e. a statement about the sufficient
number of biopsies (see recommendation 2)
– In case of insufficiently labelled containers, feedback to
the clinicians that the origin of the biopsies cannot reli-
ably be assessed, limiting assessment for IBD diagnosis.
– Potential limitations due to biopsy orientation or artefacts
Assessment of certain features such as distribution of
changes or presence and extent of a basal plasmacytosis is
limited if the material is insufficient and poorly oriented.
Use of acetate strips can be helpful for proper biopsy
orientation [45, 103].
Recommendation 6 The histological assessment should eval-
uate the distribution of overall findings, presence of chronic
injury and activity of inflammation (vote: strong consensus
(100%), level of evidence: 1a–3b, recommendation grade: C).
Evidence and decision
Distribution
Evaluating the distribution of microscopic changes can serve as
a quantitative marker for assessing overall deviations from nor-
mal mucosa. It particularly pertains to the pattern and amount of
tissue involved by chronic injury and active inflammation. The
abnormalities can vary within a single biopsy, within different
biopsies from the same site as well as among different anatom-
ical sites. This heterogeneity of disease involvement is typical
of CD but can also be seen in UC especially after treatment [60,
66–73, 75, 76, 78–91, 93] (EL 1b–2b).
Terms that are sometimes used by pathologists to assess
disease involvement, such as “diffuse”, “patchy” or “focal”,
are ill-defined and can be subjective. It is preferable to use
alternative terms such as “continous between sites”,
“discontinous between sites” or “segmental” (anatomically
non-continuous) [14] (EL 2a). Assessing the distribution of
changes is helpful for distinguishing UC from CD.
Moreover, in the course of known IBD, reporting the distri-
bution of changes can provide important information regard-
ing response to treatment in a quantitative fashion [4, 60–62,
74, 104, 105] (EL 1a–2a).
Chronicity
As most adult IBD patients present after at least 6 weeks of
symptoms, features of chronic injury are often already dis-
cernible on their GI biopsies at initial diagnosis [10, 106]
(EL 2a–2b). Features of chronic injury include architectural
distortion and chronic inflammatory infiltrates in the lamina
propria [10] (EL 2a). Basal plasmacytosis is probably the
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earliest sign of chronic injury and has proven to be the stron-
gest and highest reliable predictor of IBD. This feature was
demonstrated to achieve almost perfect intrarater as well as
substantial interrater reproducibility rates and can have signif-
icant prognostic implications. Moreover, on rectal biopsy
specimens, basal plasmacytosis has been shown to be one of
several independent predictors of earlier relapse in UC pa-
tients [9, 10, 21, 29, 107, 108] (EL 2a–3b). Another feature
of chronic injury, architectural distortion, is typically not seen
before 15 days of symptoms. However, it is present in more
than 75% of patients after 4 months [10, 16] (EL 2a). This
feature is also associated with almost perfect intraobserver and
substantial interobserver agreement rates [107] (EL 2b). Some
of the existing scoring indices for evaluating UC disease ac-
tivity do not include architectural distortion, as this feature
was not considered to be a marker for disease activity and
was also considered unlikely to be responsive to therapy.
This, however, proved to be false, as complete histologic mu-
cosal normalization is now an attainable treatment goal [10,
37, 104, 109] (EL 1b–2b). Crypt architectural distortion may,
in fact, be the only feature able to distinguish between remis-
sion and true histological normalization, given the feature’s
lengthier persistence. This is in contrast to basal
plasmacytosis, which may diminish earlier with longstanding
or treated disease [10, 45, 110] (EL 2a–3b). Additional fea-
tures of chronic injury are Paneth cell metaplasia (especially
distal the splenic flexure), pseudopolyps, hypertrophy of the
muscularis mucosae and submucosal fibrosis [105] (EL 2a).
The role of increased eosinophils in IBD is unclear.
Eosinophils are part of the normal mucosa, and their number
is highly variable [93] (EL 2a). Due to a lack of reproducibility
and only moderate interobserver agreement, the ECCO rec-
ommended that eosinophils alone should not be used as a
marker of histological activity in UC [16, 41, 106] (EL 2a).
Activity
Disease activity as measured histologically is ascertained by
the presence of neutrophilic granulocytes and their damage to
the epithelium. Cryptitis, crypt abscess formation as well as
erosions and ulcerations represent the spectrum of active in-
flammation in order of increasing severity [11, 12, 14, 111,
112] (EL 1a–2b). Whilst some question the significance and
reproducibility of histologic activity, the presence of acute
inflammatory infiltrates is actually associated with a twofold
to threefold increased risk of relapse within 12 months of
follow-up and an increased use of systemic corticosteroids,
colectomy and hospitalization within 3 years of follow-up
[20, 113] (EL 2b). Moreover, assessing for acute inflammato-
ry infiltrates such as neutrophils in the lamina propria,
intraepithelial neutrophils, erosions or ulceration attained
good reproducibility in existing scoring systems [107, 109,
114–116] (EL 2b).
Recommendation 7 The scoring system (the IBD-DCA score)
developed by the consensus group based on the factors of
distribution (D) of changes, chronic injury (C) and activity
of inflammation (A) is a proposal for a standardized and
user-friendly tool for histologic activity assessment (vote:
strong consensus (98%), level of evidence: 2b, recommenda-
tion grade: B).
The proposed “Inflammatory Bowel Disease –
Distribution, Chronicity, Activity” (IBD-DCA) score com-
prises the three parameters—distribution (D), chronicity (C)
and activity (A)—and is determined in that order. The indi-
vidual items constituting the parameters C and A were select-
ed on the basis of previous research, with particular selection
of features that have achieved good reliability in existing scor-
ing systems in order to be eligible candidates for the index
development (supplemental Table 2).
Distribution parameter (D)
Parameter D is used to estimate the overall extent of mucosal
abnormalities, regardless of whether they represent architec-
tural distortion, chronic inflammation or active inflammatory
infiltrates. D0 is assigned for completely normal mucosa with-
out any pathological changes. D1 is assigned if changes are
present in less than 50% of all tissue fragments. D2 is assigned
for changes that involve 50% or more of the tissue.
Chronicity parameter (C)
Parameter C encompasses crypt architectural distortion as
well as elevated lymphoplasmacytic cell count in the lamina
propria (including basal plasmacytosis). C0 refers to mucosa
without chronic changes, i.e. absence of elevated
lymphoplasmacytic cell count and absence of crypt architec-
tural distortion. C1 refers to crypt distortion and/or mildly
elevated lamina propria lymphoplasmacytosis (mildly more
lymphocytes and plasma cells than in the normal mucosa).
C2 necessitates a marked elevated lymphoplasmacytic cell
count in the lamina propria regardless of the additional pres-
ence of crypt distortion. Amarked basal lymphoplasmacytosis
is also assessed as C2.
Activity parameter (A)
Parameter A refers to the presence and degree of tissue in-
volvement by neutrophilic granulocytes. A0 is assessed in
the absence of neutrophilic granulocytes. The number of neu-
trophils that are allowed in a normal lamina propria ranges in
the literature between 0 and 1 [17, 93] (EL 2a). Neutrophils
are not normally present in the surface or crypt epithelium [93]
(EL 2a). Therefore, A1 is assessed for an increase of two or
more neutrophils in the lamina propria in one high-power field
(HPF) or one or more neutrophils in the epithelium (as in
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cryptitis or neutrophils in the surface epithelium). To reach the
intestinal lumen, neutrophils must first exit the blood vessels,
migrate across the lamina propria and finally cross the epithe-
lial barrier in that order [77] (EL 2a). Therefore, A2 is assigned
in the presence of crypt abscesses, erosion or ulceration as
they have breaks of the mucosal barrier in common.
A validation of the IBD-DCA score was performed after
the meeting (Lang-Schwarz et al., submitted).
Figure 1 shows the proposed algorithmic assessment of the
IBD-DCA score.
Recommendation 8 The pathology report can include routine
text as well as the IBD-DCA score as qualitative and quanti-
tative information for clinicians (vote: consensus (93%), level
of evidence: 5, recommendation grade: D).
Evidence and decision The IBD-DCA score is not intended to
replace the pathologist’s individual text reports, but it can act
as an additional tool to summarize histologic activity qualita-
tively and quantitatively. Clinicians and pathologists in their
professional partnerships may already have established means
of relaying important patient information with one another
through the language of their individual reports. The addition-
al proposed benefit in reporting the IBD-DCA score, however,
is its facilitation in disease monitoring, given that each param-
eter can be quickly and easily compared to previous findings
during a patient’s follow-up.
Example reports:
– Ulcerative proctitis, marked activity; IBD-DCA score:
D2, C2, A2
– Ulcerative proctitis, remission; IBD-DCA score: D1, C1,
A0
– Ulcerative proctitis, histologic mucosal healing; IBD-
DCA-score: D0, C0, A0
Recommendation 9 Activity scoring is ideally performed for
every container separately (vote: consensus (83%), level of
evidence: 1b–3b, recommendation grade: C).
Evidence and decision Scoring each site separately may help
distinguish CD from UC diagnostically. A discontinuous
and focal pattern of disease involvement is typical for CD,
whereas UC classically shows diffuse mucosal inflamma-
tion [4, 108] (EL 2a–3b). There is also a known gradient of
disease severity that increases from proximal to distal co-
lon in UC, versus the opposite pattern in CD in many
cases, which is helpful in distinguishing both entities [4]
(EL 2a). Performing the above scoring index for each gas-
trointestinal biopsy site can, in fact, highlight these
distinguishing attributes and support the diagnosis.
Secondly, as treatment is able to alter the usual distribution
of IBD and therapy response can vary between bowel seg-
ments, the participants agreed that activity scoring accord-
ing to the IBD-DCA score should be performed for each
designated site [61, 66–70] (EL 1b–2b). Nevertheless, ef-
fective scoring obviously depends on the endoscopist’s
sampling, as detailed in statements above. Moreover, scor-
ing and reporting each site if diagnosis and result are ex-
actly the same for every container may not be necessary
and a representative single score encompassing those parts
could be done in such situations.
– Example: ulcerative pancolitis, markedly active in sig-
moid (D2C2A2), mildly active in all other sites
(D2C1A1)
Recommendation 10 The IBD-DCA score is appropriate for
use in daily routine practice (vote: strong consensus (95%),
level of evidence: 5, recommendation grade: D).
Evidence and decision The design of the IBD-DCA score is
intended to be simple and user-friendly, with the purpose of
emulating the manner in which pathologists intuitively assess
samples from low to high power magnification in daily prac-
tice. Therefore, it is well suited to be applied to biopsy spec-
imen in daily routine diagnostics as well as clinical trials. It
can be applied to biopsies from UC as well as CD patients.
However, its significance in CD and also its applicability to
the upper GI tract have to be further investigated. The valida-
tion of the index has proven its reproducibility, feasibility,
construct validity as well as its ability to provide reliable in-
formation about response to treatment (Lang-Schwarz et al.,
submitted).Fig. 1 Proposed stepwise algorithmic assessment of the ID-DCA score
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Conclusion and further perspectives
Assessing the presence and degree of disease activity in IBD
patients is important for developing optimal therapeutic strat-
egies and timing of follow-up [117–119]. As UC activity
scoring warrants both endoscopic and histologic evaluations,
there is a need for standardized biopsy procedures and a sim-
ple, validated scoring system that can be used globally.
Moreover, such a scoring index should be able to discriminate
between quiescence and histologic mucosal healing as histo-
logic mucosal healing is emerging as the desired therapeutic
goal. Histological mucosal healing is not well defined to date.
In their “Histology Position 3.4”, the ECCO refers to “return
to normal” as the strictest definition of histological remission
[41]. A new key feature of histologic mucosal healing might
therefore lie in identifying the absence of crypt architectural
distortion, thus distinguishing between quiescent UC (which
has architectural distortion) and true histological normaliza-
tion (which looks like normal colon) [10, 74]. Two recent
studies by Christensen et al. [37, 120] suggest that histologic
normalization differs clinically from histologic quiescence by
being independently associated with increased relapse-free
survival in UC and CD, reduced medication escalation and
reduced corticosteroid use [37, 120]. To date, many different
scoring systems exist for assessing histologic activity in UC
and CD. The Cochrane Collaboration recently reviewed 14
different histologic scoring systems for CD as well as 30 in-
dices for UC by highlighting their different advantages and
disadvantages [39, 40]. Some of the systems are simple, whilst
others are very detailed. For UC, the Nancy Histological Index
(NHI) and the Robarts Histopathology Index (RHI) have un-
dergone the most validation, even if the feasibility of these
indices has not been assessed [109, 114]. Therefore, the
ECCO recommended recently the use of both indices for ran-
domized control trials in ulcerative colitis and the use of the
NHI for observational studies or in clinical practice [41].
However, neither the NHI nor the RHI includes architec-
tural features, which means that they cannot distinguish be-
tween histologic quiescent disease (in which crypt architectur-
al distortion is often the only visible feature) and histological
complete normal mucosa. As for CD, the existing indices have
yet to be validated and none of them is recommended for use
to date.
In order to address such issues, the International Consensus
Conference on IBD Activity Scoring assented on the above
statements with the goal of maximizing diagnostic informa-
tion from biopsies as relevant in the modern era of IBD ther-
apy and of optimizing communication between clinicians and
pathologists to enhance patient care. The statements are in line
with published recommendations from internationally recog-
nized organizations such as ECCO, the BSG, the ACG, the
ASGE and the WGO, and they are intended to consolidate the
factors most relevant to patient care and raise awareness
regarding the need for these clinically relevant matters to be
applied more consistently in daily practice. The group agreed
on ten statements which received a high level of agreement.
Since the participants represented centres from different coun-
tries worldwide, this agreement suggests notable international
recognition on the topics considered.
Additionally, we present the IBD-DCA score, a proposal
for an international, consensus-approved histologic activity
scoring index, intended for use in routine practice and clinical
trials. The scoring index is able to distinguish between quies-
cence and true histological mucosal healing. Furthermore, it
includes a statement on the quantity as well as the quality of
inflammatory changes. Apart from normal, grading of chro-
nicity and activity is reported in a two-tiered fashion in the
IBD-DCA score, distinguishing only between low- and high-
level inflammatory changes. The terms “low-” and “high-
grade” are, however, intentionally omitted to avoid confusion
as these terms are traditionally used for dysplasia. The sim-
plicity of the index makes it likely to be used by pathologists
and also to be accepted by the clinicians. It should be appli-
cable for UC and may also be applicable for CD in both the
upper and lower GI tract. Noteworthy that the index may be
used for patients with proven IBD during follow-up to assess
changes over time. However, the main limitation of this study
is the fact that the proposed index has not been tested prospec-
tively so far. Validation by an independent research group is
clearly necessary. Also, its use in CD needs further validation
studies, due to the potential limitations of histologic activity
scoring in the discontinuous disease involvement inherent in
the nature of CD.
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